Glenmark Pharmaceuticals Inc., USA FDA Inspection Record

FEI 3005658103 · Inspections, Form 483s, warning letters and import refusals

Glenmark Pharmaceuticals Inc., USA is an FDA-inspected facility (FEI 3005658103) located in Elmwood Park, NJ, US. RegDataLab tracks 3 FDA inspections and 3 compliance actions at this facility.

What FDA found at this site

Latest inspection
Dec 5, 2016: No Action Indicated (NAI)
Inspections on record
3 (1 VAI, 2 NAI)
Last OAI inspection
None on record
Warning letters
3 listed by FDA for this FEI, latest Mar 16, 2010
Recalls as the recalling firm
65, latest Oct 9, 2026
Import refusals
1

A Form 483 lists an inspector's observations. OAI means FDA recommends regulatory and/or administrative action. A warning letter is FDA's formal enforcement notice. No record here does not establish that a site is safe. Check this site on FDA's Data Dashboard.

Inspections and what FDA cited

Newest first. Citations are the inspector observations FDA publishes for the inspection.

DateResultWhat FDA cited
Dec 5, 2016No Action Indicated (NAI)No citations listed
Sep 9, 2011No Action Indicated (NAI)No citations listed
Jun 29, 2010Voluntary Action Indicated (VAI)Complaint Handling Procedure (21 CFR 211.198(a))
Failure to develop written procedures (21 CFR 314.80(b))
Late submission of quarterly safety reports (21 CFR 314.80(c)(2))

Recalls

Showing the 10 most recent of 65 recalls. Recalls FDA's Enforcement Report lists with this FEI as the recalling firm. The recalling firm is not always the site that made the product. Search FDA's Enforcement Report by recall number.

DateClassRecallProduct and reason
Oct 9, 2026Class IID-0074-2027Abiraterone Acetate Tablets USP 500 mg, 60-count bottles, Rx only, Distributed by…
Labeling: Not Elsewhere Classified
Sep 10, 2026Class IID-0015-2027Clindamycin Phosphate Foam, 1%, FOR TOPICAL USE ONLY, Rx only, 100 g can, Manufactured…
Defective Container: Firm received customer complaints of damaged and leaking product.
Jul 23, 2026Class IID-0731-2026Azelaic Acid Gel, 15%, 50 gram tubes, For Topical Use only, Rx only, Distributed by…
CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were…
May 27, 2026Class IID-0588-2026Alyacen 7/7/7, Norethindrone and Ethinyl Estradiol Tablets USP, 0.5mg/0.035mg…
Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.
Dec 30, 2025Class IID-0246-2026Ondansetron Orally Disintegrating Tablets, USP, 4mg, 30 Tablets (3 blistercards each…
Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed…
Nov 21, 2025Class IIID-0199-2026Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 2.5 mg/6.25 mg, packaged as (a)…
Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe
Nov 18, 2025Class IIID-0222-2026Nebivolol Tablets, 20 mg, 90 Tablets, Rx Only, Manufactured by: Glenmark Pharmaceuticals…
Cross Contamination with Other Products
Sep 17, 2025Class IID-0662-2025Azelaic Acid Gel, 15%, 50 grams, For Topical Use Only, Rx only, Manufactured by: Glenmark…
CGMP Deviations: Market complaints received for gritty texture (grainy)
Sep 3, 2025Class IID-0021-2026Viorele, Desogestrel and Ethinyl Estradiol, USP, 0.15 mg/ 0.02 mg and Ethinyl Estradiol…
Failed Impurities/Degradation Specifications
Aug 8, 2025Class IID-0583-2025Theophylline extended-release tablets 400mg, 100-count bottle, Rx only, Manufactured by…
Failed Dissolution Specifications: Failure results (above) were reported for the Dissolution (by UV) test for commercial annual stability at…

FDA record score

100 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. The records below add up to 125.8; the score stops at 100.

Counted on Nov 17, 2026, method version 1. It counts records and does not judge the site: a low number does not establish that a site is safe, and sites that FDA inspects more often can collect more points. How this is counted.

50 records behind this number
RecordDatePoints x age weightAdds
Class I recall D-0604-2024, this FEI as the recalling firmMay 30, 202415 x 0.69
Class II recall D-0074-2027, this FEI as the recalling firmOct 9, 20264 x 14
Class II recall D-0015-2027, this FEI as the recalling firmSep 10, 20264 x 14
Class II recall D-0731-2026, this FEI as the recalling firmJul 23, 20264 x 14
Class II recall D-0588-2026, this FEI as the recalling firmMay 27, 20264 x 14
Class II recall D-0246-2026, this FEI as the recalling firmDec 30, 20254 x 14
Class II recall D-0662-2025, this FEI as the recalling firmSep 17, 20254 x 14
Class II recall D-0021-2026, this FEI as the recalling firmSep 3, 20254 x 14
Class II recall D-0583-2025, this FEI as the recalling firmAug 8, 20254 x 14
Class II recall D-0577-2025, this FEI as the recalling firmAug 7, 20254 x 14
Class II recall D-0587-2025, this FEI as the recalling firmAug 6, 20254 x 14
Class II recall D-0452-2025, this FEI as the recalling firmMay 15, 20254 x 14
Class II recall D-0314-2025, this FEI as the recalling firmMar 13, 20254 x 14
Class II recall D-0309-2025, this FEI as the recalling firmMar 11, 20254 x 14
Class II recall D-0448-2025, this FEI as the recalling firmFeb 28, 20254 x 14
Class II recall D-0231-2025, this FEI as the recalling firmJan 29, 20254 x 14
Class II recall D-0215-2025, this FEI as the recalling firmJan 22, 20254 x 14
Class II recall D-0159-2025, this FEI as the recalling firmDec 11, 20244 x 14
Class II recall D-0093-2025, this FEI as the recalling firmNov 1, 20244 x 0.62.4
Class II recall D-0006-2025, this FEI as the recalling firmSep 24, 20244 x 0.62.4
Class II recall D-0660-2024, this FEI as the recalling firmAug 30, 20244 x 0.62.4
Class II recall D-0643-2024, this FEI as the recalling firmJul 31, 20244 x 0.62.4
Class II recall D-0621-2024, this FEI as the recalling firmJul 22, 20244 x 0.62.4
Class II recall D-0612-2024, this FEI as the recalling firmJun 28, 20244 x 0.62.4
Class II recall D-0534-2024, this FEI as the recalling firmMay 13, 20244 x 0.62.4
Class II recall D-0532-2024, this FEI as the recalling firmMay 10, 20244 x 0.62.4
Class II recall D-0472-2024, this FEI as the recalling firmApr 17, 20244 x 0.62.4
Class II recall D-0430-2024, this FEI as the recalling firmMar 26, 20244 x 0.62.4
Class II recall D-0259-2024, this FEI as the recalling firmJan 4, 20244 x 0.62.4
Class II recall D-0123-2024, this FEI as the recalling firmNov 7, 20234 x 0.62.4
Class II recall D-0092-2024, this FEI as the recalling firmOct 23, 20234 x 0.62.4
Class II recall D-0095-2024, this FEI as the recalling firmOct 20, 20234 x 0.62.4
Class II recall D-1171-2022, this FEI as the recalling firmJun 29, 20224 x 0.62.4
Class II recall D-1305-2022, this FEI as the recalling firmJun 29, 20224 x 0.62.4
Class II recall D-0791-2022, this FEI as the recalling firmApr 25, 20224 x 0.62.4
Class II recall D-0820-2021, this FEI as the recalling firmAug 27, 20214 x 0.251
Class II recall D-0639-2020, this FEI as the recalling firmDec 17, 20194 x 0.251
Class II recall D-0156-2020, this FEI as the recalling firmOct 22, 20194 x 0.251
Class II recall D-1586-2019, this FEI as the recalling firmJul 23, 20194 x 0.251
Class II recall D-1340-2019, this FEI as the recalling firmJun 3, 20194 x 0.251
Class II recall D-1120-2019, this FEI as the recalling firmMar 25, 20194 x 0.251
Class II recall D-0350-2019, this FEI as the recalling firmDec 26, 20184 x 0.251
Class II recall D-0336-2018, this FEI as the recalling firmNov 20, 20174 x 0.251
Class II recall D-1229-2014, this FEI as the recalling firmMar 18, 201410 years or older, so it adds no points0
Class II recall D-1701-2012, this FEI as the recalling firmJul 6, 201210 years or older, so it adds no points0
Class II recall D-1134-2012, this FEI as the recalling firmDec 6, 201110 years or older, so it adds no points0
Inspection classified VAIJun 29, 201010 years or older, so it adds no points0
Warning letter on FDA's dashboard, which does not show close-outsMar 16, 201010 years or older, so it adds no points0
Warning letter on FDA's dashboard, which does not show close-outsOct 13, 200910 years or older, so it adds no points0
Warning letter on FDA's dashboard, which does not show close-outsMar 30, 200910 years or older, so it adds no points0

When each source was last refreshed

FDA sources behind this page and when RegDataLab last refreshed each one
RecordsLast refreshedSource as ofStatus
InspectionsNov 16, 2026Newest record Nov 5, 2026Current
Inspection citationsNov 16, 2026Newest record Nov 5, 2026Current
Compliance actions (warning letters, injunctions and other action types)Nov 2, 2026Newest record Oct 29, 2026Current
Warning letter textNov 16, 2026Newest record Nov 10, 2026Current
Recalls (Enforcement Report)Nov 16, 2026Newest record Nov 11, 2026Current
Form 483s and inspection documentsNov 13, 2026Newest record Nov 12, 2026Current
Import refusalsNov 15, 2026Newest record Nov 5, 2026Current

Reviewing Glenmark Pharmaceuticals Inc., USA as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Glenmark Pharmaceuticals Inc., USA yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Facility details

Company
Glenmark Pharmaceuticals Inc., USA
Location
Elmwood Park, NJ (US)
Source
inspections

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.